TY - JOUR
T1 - Recurrence and Emergence of New Primary Tumors in Patients with Resected Pathological Stage 1A Non–Small Cell Lung Cancer
AU - the IELCART Investigators
AU - Gros, Louis
AU - Yip, Rowena
AU - Flores, Raja M.
AU - Paksashvili, Natela
AU - Zhang, Lijing
AU - Lyu, Lyu
AU - Cai, Siyang
AU - Taioli, Emanuela
AU - Yankelevitz, David F.
AU - Henschke, Claudia I.
AU - Kaufman, Andrew
AU - Lee, Dong Seok
AU - Nicastri, Daniel
AU - Wolf, Andrea
AU - Song, Kimberly
AU - Rosenzweig, Kenneth
AU - Samstein, Robert
AU - Dutta, Pinaki
AU - Gomez, Jorge
AU - Beasley, Mary Beth
AU - Zakowski, Maureen
AU - Chung, Michael
AU - Yankelevitz, David F.
AU - Henschke, Claudia I.
AU - Taioli, Emanuela
AU - Zhu, Yeqing
AU - Paksashvili, Natela
AU - Zhang, Lijing
AU - Lyu, Lyu
AU - Chan, Huiwen
AU - Zhu, Jeffrey
AU - Kantor, Sydney
AU - Lentini, Lauren
AU - Buyuk, Arzu
AU - Friedman, Adie
AU - Dreifuss, Ronald
AU - Verzosa, Stacey
AU - Yakubox, Mariya
AU - Aloferdova, Karina
AU - Stacey, Patricia
AU - De Nobrega, Simone
AU - Zhu, Jeffrey
AU - Kantor, Sydney
AU - Lentini, Lauren
AU - Hakami, Ardeshir
AU - Zhu, Jeffrey
AU - Connery, Cliff P.
AU - Schwartz, Rebecca
AU - Henschke, Claudia I.
AU - Jirapatnakul, Artit
N1 - Publisher Copyright:
Copyright © 2025 by the American Thoracic Society. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
PY - 2026/1
Y1 - 2026/1
N2 - Rationale: Lung cancer screening has made early-stage non–small cell lung cancer (NSCLC) more common and highly curable. However, evidence on post-treatment surveillance, new radiological findings, and distinguishing recurrence from new primary cancers remains limited. Objectives: Our study evaluated outcomes in patients with pathologic stage 0/1A first primary NSCLC after surgery, including overall survival and the classification of new findings as either recurrence or second primary tumors. We also explored potential improvements to current classification criteria. Methods: We analyzed 653 patients with pathologic stage 0/1A NSCLC from the IELCART cohort (2016–2023). Radiological findings were reviewed to classify lung cancer diagnoses as second primaries or recurrences using a five-step approach based on histopathology, genetics, timing, and multidisciplinary discussions. Survival was analyzed with Kaplan-Meier curves and log-rank tests. Results: Among 653 patients (61.1% women, median age 69 yr), 74 (11.3%) later had radiological findings confirmed as lung cancer, which was more frequent in men (15.7% vs. 8.5%), those with higher pack-years, and chronic obstructive pulmonary disease. New malignant events were most common in current smokers (19.1%), followed by former smokers (15.2%) and never smokers (1.6%). Of these, 30 (5%) were second primaries, and 44 (7%) were recurrences. Nonsolid cancers showed no recurrences. Recurrences peaked at 12–18 months, whereas second primaries occurred steadily at 0.6% annually. Overall survival differed significantly between patient groups (P < 0.0001), with overall survival of 58.2% with recurrences, 77.9% with new primaries, and 94.3% with no new cancer after a median follow-up of 3.5 years. Conclusion: Among 653 patients, 7% had recurrences, whereas new primaries (5%) became more frequent after 3 years, occurring steadily at 0.6% per year, with distinct survival outcomes. New malignant events were more common in men, smokers, and those with chronic obstructive pulmonary disease. Notably, all malignancies in nonsolid cancers were new primaries. These findings emphasize the need for tailored surveillance strategies.
AB - Rationale: Lung cancer screening has made early-stage non–small cell lung cancer (NSCLC) more common and highly curable. However, evidence on post-treatment surveillance, new radiological findings, and distinguishing recurrence from new primary cancers remains limited. Objectives: Our study evaluated outcomes in patients with pathologic stage 0/1A first primary NSCLC after surgery, including overall survival and the classification of new findings as either recurrence or second primary tumors. We also explored potential improvements to current classification criteria. Methods: We analyzed 653 patients with pathologic stage 0/1A NSCLC from the IELCART cohort (2016–2023). Radiological findings were reviewed to classify lung cancer diagnoses as second primaries or recurrences using a five-step approach based on histopathology, genetics, timing, and multidisciplinary discussions. Survival was analyzed with Kaplan-Meier curves and log-rank tests. Results: Among 653 patients (61.1% women, median age 69 yr), 74 (11.3%) later had radiological findings confirmed as lung cancer, which was more frequent in men (15.7% vs. 8.5%), those with higher pack-years, and chronic obstructive pulmonary disease. New malignant events were most common in current smokers (19.1%), followed by former smokers (15.2%) and never smokers (1.6%). Of these, 30 (5%) were second primaries, and 44 (7%) were recurrences. Nonsolid cancers showed no recurrences. Recurrences peaked at 12–18 months, whereas second primaries occurred steadily at 0.6% annually. Overall survival differed significantly between patient groups (P < 0.0001), with overall survival of 58.2% with recurrences, 77.9% with new primaries, and 94.3% with no new cancer after a median follow-up of 3.5 years. Conclusion: Among 653 patients, 7% had recurrences, whereas new primaries (5%) became more frequent after 3 years, occurring steadily at 0.6% per year, with distinct survival outcomes. New malignant events were more common in men, smokers, and those with chronic obstructive pulmonary disease. Notably, all malignancies in nonsolid cancers were new primaries. These findings emphasize the need for tailored surveillance strategies.
KW - NSCLC outcomes
KW - early-stage lung cancer
KW - lung cancer recurrence
KW - recurrence
KW - second primary lung cancer
UR - https://www.scopus.com/pages/publications/105033050638
U2 - 10.1513/AnnalsATS.202501-121OC
DO - 10.1513/AnnalsATS.202501-121OC
M3 - Article
C2 - 40737521
AN - SCOPUS:105033050638
SN - 2329-6933
VL - 23
SP - 132
EP - 142
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 1
ER -